Dr. Zackory Burns is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where he is a member of the technology transactions practice.
Zack advises international and domestic private and public biopharmaceutical and life sciences companies in various transactions related to the discovery, research, development and commercialization of their products. He specializes in working with clients in strategic transactions from very complex strategic alliances and collaborations to a wide range of other transactions, including license, discovery, research, development, manufacture, supply, and services agreements.
Prior to joining the firm, Zack was the lead attorney at Moderna advising its discovery and research teams. Prior to joining Moderna, Zack was an associate at two other law firms that are internationally recognized for their life science work. Before attending law school, Zack completed a post-doctoral Hellman Fellowship in Science and Technology Policy at the American Academy of Arts & Sciences and undertook scientific research on five continents.
Dr. Zackory Burns is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where he is a member of the technology transactions practice.
Zack advises international and domestic private and public biopharmaceutical and life sciences companies in various transactions related to the discovery, research, development and commercialization of their products. He specializes in working with clients in strategic transactions from very complex strategic alliances and collaborations to a wide range of other transactions, including license, discovery, research, development, manufacture, supply, and services agreements.
Prior to joining the firm, Zack was the lead attorney at Moderna advising its discovery and research teams. Prior to joining Moderna, Zack was an associate at two other law firms that are internationally recognized for their life science work. Before attending law school, Zack completed a post-doctoral Hellman Fellowship in Science and Technology Policy at the American Academy of Arts & Sciences and undertook scientific research on five continents.
- J.D., University of California, Irvine School of LawCum Laude
- D.Phil., Zoology, University of Oxford
- A.B., Ecology and Evolutionary Biology, Princeton University
- State Bar of California
- State Bar of Massachusetts
- State Bar of Michigan
- J.D., University of California, Irvine School of LawCum Laude
- D.Phil., Zoology, University of Oxford
- A.B., Ecology and Evolutionary Biology, Princeton University
- State Bar of California
- State Bar of Massachusetts
- State Bar of Michigan
BIIB131 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.
TMS and JIXING will form a collaborative partnership to globally develop TMS-007—a novel antithrombotic agent developed for the treatment of acute ischemic stroke (AIS)—with TMS regaining royalty-free Japan rights while JIXING will lead the development and commercialization of TMS-007 in the rest of the world. TMS and JIXING will join forces to expeditiously develop and launch TMS-007 globally, facilitated by the formation of a Joint Development Committee. In addition, TMS will receive an upfront payment of $5 million in the form of JIXING equity, up to $12.5 million in development milestones, up to $355 million in commercial milestones, and tiered royalties consistent with the original Option Agreement.
Concurrently, JIXING licenses to TMS exclusive Japan rights of JX09. JX09 is an oral, novel, small molecule ASI in development for the treatment of resistant and/or uncontrolled hypertension by JIXING, which is planned to enter into a first-in-human Phase 1 clinical trial in early 2024.
The Wilson Sonsini team that advised JIXING on the transactions included partners Michael Hostetler, Farah Gerdes, Mark Bellomy, Greg Broome, and Jen Fang; associates Zack Burns, TJ Tingjie Li, Ying Chen, Brandon King, Christina Fuleihan, Hee Min Noh, and Zamin Raza; and patent agent Jamie Gleason-Bremer.
For more information, please see the companies’ news release.
- Privacy Policy
- Terms of Use
- Accessibility